Tofacitinib in the Recalcitrant Cases of Alopecia Areata: A Pilot Study
June 2025
in “
International Journal of Science and Research (IJSR)
”
A pilot study investigated the efficacy and safety of oral tofacitinib in treating recalcitrant cases of alopecia areata in 20 patients aged 10-50 years over 6 months. The study found a significant decrease in the Severity of Alopecia Areata (SALT) score, with an average improvement of 27% in 19 patients, indicating effective hair regrowth. Side effects were minimal, occurring in only 3 patients. Despite the small sample size and short duration, the study concluded that a 5mg BD dose of tofacitinib is effective for alopecia areata, though proper lab monitoring is necessary for patient safety.